Aflac

Aflac is the rare US-listed insurer that earns ~70% of pretax operating income outside the United States — almost entirely from Japan, where it dominates the supplemental cancer- and medical-insurance market with roughly 25% share of policies in force. The 2026 story has two strands. First, the Bank of Japan's exit from yield-curve control has begun lifting JGB yields above 1.5%, which mechanically boosts net investment income on Aflac's $80B+ Japanese fixed-income portfolio. Second, the yen weakness that crushed translated earnings during 2022–2024 has reversed: USD/JPY traded near 145 in early 2026 versus 160 a year earlier, which adds 4-to-6% to translated Japan operating income for FY2026 alone. Aflac US (the smaller, growth-y leg) continues to deliver mid-single-digit premium growth in voluntary worksite benefits. The combined-company FY2026 EPS consensus stands near $8.10, and management just raised the dividend for the 43rd consecutive year while running a $2B annual buyback — sustained capital return that consistently exceeds the company's reported earnings.

Aflac is one of the few insurance names where ValueAct Capital still holds a notable stake (roughly 1.1% of float in the latest 13F). The activist case rests on Japan capital efficiency: Aflac Japan generates excess capital well above its dividend-to-parent ceiling, and ValueAct has publicly pushed for accelerated buybacks plus a partial divestment of the Japanese subsidiary's yen-denominated equity holdings. Other smart-money holders include Yacktman Asset Management and Mawer New Manager — both deep-value names that own Aflac for the rare combination of low P/E and high book-value compounding. Smart money has been adding under $105 throughout 2025; that level marks roughly 1.5× tangible book, the historical 10-year floor outside of pandemic crisis lows.

Aflac trades at 13.1× forward earnings and 1.7× tangible book value — modest discount to the US life-insurance median of 14.5× and a substantial premium to MetLife (8.1×) and Prudential (7.4×). The premium is justified by Aflac's superior ROE (above 16% versus low double-digits for diversified peers), low credit-asset risk (largely sovereign and high-grade corporate JGBs), and the durable Japan-Post duopoly position in supplemental insurance. Free-cash-flow yield stands at 9% — capital return is essentially fully funded by FCF, with no dilution. Bull case: yen stays sub-150 and BoJ yields rise to 2.0%+ — fair value $135. Bear case: yen returns to 160 plus another Japan-Post incident — fair value $90.

1. August 5, 2026: Q2/2026 earnings — Japan premium growth and net investment income with first full quarter of higher JGB-reinvestment yields.
2. November 4, 2026: Q3/2026 + FY guidance refresh; expected announcement of next buyback authorization ($2.5B+) plus the 44th consecutive dividend hike.
3. January 2027: BoJ policy meeting — if rates rise above 1.0% policy rate, Aflac Japan reinvestment tailwind accelerates by an estimated $200M+ in incremental annual NII.

Aflac is the ugly-duckling insurer that almost no growth investor ever owns, but income and value funds quietly accumulate. The Japan cash-cow dynamics are the closest thing to a regulated utility you will find in supplemental insurance — high market share, sticky distribution, near-100% retention. The yen reversal and BoJ exit are two compounding tailwinds that the market is still pricing as one-off effects rather than a multi-year story. I would size Aflac at 2–4% in an income or dividend-growth portfolio and add on any dip below $108. The boring answer is the right answer here: hold, collect the dividend, watch the buyback shrink the share count by 3.5% a year, and check back in 2030.